Mary Barton-Rau currently serves as the Proxy Product Owner for Digital Transformation at the Messenger RNA Center of Excellence within Sanofi, where she leverages her extensive background in software engineering and product management to spearhead innovative projects that redefine the landscape of biopharmaceutical research and...
Mary Barton-Rau currently serves as the Proxy Product Owner for Digital Transformation at the Messenger RNA Center of Excellence within Sanofi, where she leverages her extensive background in software engineering and product management to spearhead innovative projects that redefine the landscape of biopharmaceutical research and development. With over a decade of experience in AI delivery and digital transformation, Mary plays a pivotal role in enhancing operational efficiencies across the organization. Her contributions to the Data Continuum project have significantly improved data accessibility for scientists, enabling them to leverage advanced analytics and drive breakthroughs in messenger RNA technology.
In her role, Mary collaborates closely with the Scientific Product Owner to develop new digital products that align with Sanofi's strategic objectives. By utilizing the Scrum framework, she effectively facilitates agile project management, ensuring that cross-functional teams are aligned and focused on delivering high-quality outcomes. Her adept management of user stories and logical data models has streamlined workflows, while her rigorous acceptance testing and verification processes guarantee that products meet the highest standards of excellence.
Mary’s expertise extends beyond technical acumen; she is also a skilled coach, fostering an environment of continuous improvement and collaboration. Her proficiency in cloud applications and business intelligence further enhances her ability to deliver impactful solutions that drive meaningful business outcomes. As a leader in digital transformation, Mary Barton-Rau is committed to harnessing technology to advance scientific discovery and ultimately improve patient outcomes in the ever-evolving pharmaceutical landscape.
